CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · IEX Real-Time Price · USD
6.35
-0.09 (-1.40%)
Jul 19, 2024, 4:00 PM EDT - Market closed
CASI Pharmaceuticals Employees
CASI Pharmaceuticals had 176 employees as of December 31, 2023. The number of employees decreased by 48 or -21.43% compared to the previous year.
Employees
176
Change (1Y)
-48
Growth (1Y)
-21.43%
Revenue / Employee
$192,494
Profits / Employee
-$153,182
Market Cap
85.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Alpha Teknova | 211 |
Hyperfine | 131 |
AlloVir | 112 |
DBV Technologies | 105 |
Verastem | 73 |
Boundless Bio | 72 |
Clearside Biomedical | 30 |
Benitec Biopharma | 18 |
CASI News
- 2 days ago - CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - PRNewsWire
- 14 days ago - CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - PRNewsWire
- 25 days ago - CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company - PRNewsWire
- 25 days ago - CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He - PRNewsWire
- 2 months ago - CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) - PRNewsWire
- 2 months ago - CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 4 months ago - CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 4 months ago - CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China - PRNewsWire